Amplitude Vascular Systems Secures $36M to Advance Treatment for Calcified Arterial Disease

Medical device company raises $36M for emitter-free IVL platform

Boston-based Amplitude Vascular Systems is busy investigating the performance of its Pulse IVL platform in a wide variety of patient populations.

AVS secures $36m to support US launch of Pulse IVL device

AVS has announced the completion of a $36m Series B financing round to support the peripheral commercial launch of its Pulse IVL.The post AVS secures $36m to support US launch of Pulse IVL device appeared first on Medical Device Network.

Amplitude Vascular Systems Secures $36M to Advance Treatment for Calcified Arterial Disease

What You Should Know: –  Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its novel PULSE IVL™ platform, announced today that it has completed a Series B round of financing of $36M.  –  The funding will support the U.S. peripheral commercial launch as well as U.S. coronary and carotid IDE trials for the company’s Pulse Intravascular Lithotripsy™ (PIVL™)…

AVS completes US$36 million Series B financing ahead of IVL US commercial launch - Interventional News

AVS console Amplitude Vascular Systems (AVS) recently announced that it has completed a Series B round of financing of US$36 million. The funding will support the US peripheral commercial launch as well as US coronary and carotid investigational device exemption (IDE) trials for the company’s Pulse intravascular lithotripsy (PIVL) device. “We are pleased to see strong, sustained investor excitement around this technology,” said Mark Toland, chai…

AVS completes US$36 million Series B financing ahead of IVL US commercial launch - Cardiovascular News

Amplitude Vascular Systems (AVS) recently announced that it has completed a Series B round of financing of US$36 million. The funding will support the US peripheral commercial launch as well as US coronary and carotid investigational device exemption (IDE) trials for the company’s Pulse intravascular lithotripsy (PIVL) device. “We are pleased to see strong, sustained investor excitement around this technology,” said Mark Toland, chairman of the …

AVS Completes a $36M Series B Financing Ahead of IVL U.S. Commercial Launch - Medical Alley

January 28, 2025 08:00 AM Eastern Standard Time BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease with its novel PULSE IVL platform, announced today that it has completed a Series B round of financing of $36M. The funding will support the U.S. peripheral commercial launch as well as U.S. coronary and carotid IDE trials for the company’s…